133 related articles for article (PubMed ID: 17765427)
1. Safety of intravitreal injections in patients receiving warfarin anticoagulation.
Dayani PN; Siddiqi OK; Holekamp NM
Am J Ophthalmol; 2007 Sep; 144(3):451-3. PubMed ID: 17765427
[TBL] [Abstract][Full Text] [Related]
2. Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections.
Meyer CH; Eter N
Am J Ophthalmol; 2008 Feb; 145(2):386-7. PubMed ID: 18222195
[No Abstract] [Full Text] [Related]
3. Compassionate use of intravitreal pegaptanib in patients with age-related macular degeneration.
Ricci F; Missiroli F; Cedrone C; Grossi M; Regine F
Semin Ophthalmol; 2010; 25(1-2):16-20. PubMed ID: 20507192
[TBL] [Abstract][Full Text] [Related]
4. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
Quiram PA; Hassan TS; Williams GA
Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients.
Mason JO; Frederick PA; Neimkin MG; White MF; Feist RM; Thomley ML; Albert MA
Retina; 2010 Oct; 30(9):1386-9. PubMed ID: 20924260
[TBL] [Abstract][Full Text] [Related]
7. Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration.
Olson JM; Scott IU; Kerchner DL; Kunselman AR
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(5):455-9. PubMed ID: 24044707
[TBL] [Abstract][Full Text] [Related]
8. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
9. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
11. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
12. RPE tears after pegaptanib treatment in age-related macular degeneration.
Chang LK; Flaxel CJ; Lauer AK; Sarraf D
Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009
[TBL] [Abstract][Full Text] [Related]
13. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
14. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization.
Krishnan R; Goverdhan S; Lochhead J
Clin Exp Ophthalmol; 2009 May; 37(4):384-8. PubMed ID: 19594565
[TBL] [Abstract][Full Text] [Related]
15. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
Williams AJ; Fekrat S
Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
Frenkel RE; Mani L; Toler AR; Frenkel MP
Am J Ophthalmol; 2007 Jun; 143(6):1034-5. PubMed ID: 17524771
[TBL] [Abstract][Full Text] [Related]
18. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
19. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
[TBL] [Abstract][Full Text] [Related]
20. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
